NFKB1 and lung carcinoma: To test this hypothesis, we pretreated well-established human lung cancer cell lines with TQ, specific MAPK inhibitors, or an NF-κB inhibitor, followed by LPS stimulation, and subsequently measured the levels of hsa-miR-199a-3p, COX-2, and PGE2.